-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On July 28, Golly announced that the Chinese Phase 2b clinical trial of anti-PD-L1 antibody ASC22 combined with nucleoside (acid) analogues has completed the enrollment of 149 patients with chronic hepatitis B and achieved good interim results
The good interim result of ASC22 was a randomized, single-blind, placebo-controlled multicenter clinical trial conducted in China
According to the efficacy data as of July 20, 2021, the interim data analysis showed that in the 1 mg/kg ASC22 combined with nucleoside (acid) analog group administered once every two weeks, a decrease in hepatitis B surface antigen was observed.
According to the pharmacokinetic data of phase 2b clinical trials of 1 mg/kg and 2.
In terms of safety, the interim data analysis showed that in the 1 mg/kg ASC22 combined nucleoside (acid) analog group, the incidence of any adverse events (75%) was the same as that in the placebo combined nucleoside (acid) analog group ( 73%) is equivalent
"I am very pleased.
Dr.
Dr.
Note: This article aims to introduce the progress of medical and health research, not to recommend treatment options
Note: This article aims to introduce the progress of medical and health research, not to recommend treatment options
Reference
[1]Gally announced that subcutaneous injection of PD-L1 antibody ASC22 (Envolimab) China Phase IIb hepatitis B trial completed 149 patients and achieved good interim results.
[1]Gally announced that subcutaneous injection of PD-L1 antibody ASC22 (Envolimab) China Phase IIb hepatitis B trial completed 149 patients and achieved good interim results.
Retrieved June 28, 2021, from https://www.
prnasia.
com/story/327248-1.
shtml
